Skye Bioscience, Inc. (SKYE) Research

Skye Bioscience, Inc. is a biopharmaceutical firm focused on the discovery, development, and commercialization of cannabinoid-based therapeutics, primarily targeting various ophthalmic conditions. The company's leading drug candidate, SBI-100, is currently undergoing Phase I clinical trials for the treatment of glaucoma and ocular hypertension. In addition, Skye Bioscience is developing SBI-200, which is in preclinical stages, to manage and treat a spectrum of eye diseases such as uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. The company, originally named Emerald Bioscience, Inc., rebranded to Skye Bioscience, Inc. in January 2021. Founded in 2012, its headquarters are situated in San Diego, California.

Market snapshot

Symbol
SKYE
Price
$0.71
Day change
-0.59%
Market cap
$24.9M
P/E ratio
-0.49x
52-week range
0.566-5.75
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$12.00

Peer companies

  • Aligos Therapeutics, Inc. (ALGS)
  • Barinthus Biotherapeutics plc (BRNS)
  • CEL-SCI Corporation (CVM)
  • INmune Bio, Inc. (INMB)
  • Kezar Life Sciences, Inc. (KZR)
  • LAVA Therapeutics N.V. (LVTX)
  • Mersana Therapeutics, Inc. (MRSN)
  • PDS Biotechnology Corporation (PDSB)

Recent insider activity

  • Sharp John P — trade (0 shares) on 2026-03-31
  • Smith Karen L. — A-Award (75000 shares) on 2026-03-31
  • Twitty Christopher — A-Award (200000 shares) on 2026-03-31
  • Twitty Christopher — A-Award (150000 shares) on 2026-03-31
  • Twitty Christopher — A-Award (75000 shares) on 2026-03-31

Open Skye Bioscience, Inc. (SKYE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.